Key clinical point: The strategy of rapid alteration of drugs to overcome imatinib resistance mutation in gastrointestinal stromal tumor (GIST) is feasible but was ineffective.
Major finding: There were no objective responses among 12 patients treated continuously with 3 days of sunitinib (Sutent) followed by 4 days of regorafenib (Stivarga). Although four patients had stable disease in the short term, in each case the disease progressed within 16 weeks.
Study details: Phase Ib clinical trial in 12 patients with heavily pre-treated metastatic GIST.
Disclosures: The study was supported by an ASCO Young Investigator Award, Pfizer, and Bayer. Dr. Serrano disclosed honoraria from Bayer, a consulting or advisory role for Deciphera, research funding from Bayer and Deciphera, and travel accommodations and expenses from Pfizer.
Source: Serrano C et al. ASCO 2018 Abstract 11510.
Serrano C et al. ASCO 2018 Abstract 11510.
This Week's Must Reads
Must Reads in GIST
Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.
Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
Two novel TKIs better than one in GIST with multiple KIT mutations, Wagner AJ et al. ASCO 2018, Abstract 11509.
In GIST, KIT inhibitor may be of benefit in all post-imatinib lines of therapy, George S et al. ASCO 2018. Abstract 11511.
Sunitinib with regorafenib falls short for metastatic GIST, Serrano C et al. ASCO 2018 Abstract 11510.